Managing Biometrics in 2026: What Every Biostats Leader Must Know About AI
Hill Research and AI on the Hill are launching 2026 with a live panel discussion bringing together leaders from regulatory, biostatistics, legal, and AI-driven CRO communities. This inaugural webinar examines how artificial intelligence is transforming biometrics workflows in clinical development and what accountability mechanisms will emerge as adoption accelerates across the industry.
As organizations expand their reliance on AI tools, biometrics teams face a critical transition. The initial phase of experimentation has concluded, replaced by demands for accountability. This discussion addresses what this transformation means for statistical programming, quality frameworks, regulatory submissions, and legal preparedness as organizations anticipate greater FDA engagement.
Significance for 2026
Throughout the past year, numerous organizations tested AI applications in biometrics and clinical data operations. Current expectations have shifted markedly. Sponsors and contract research organizations must now demonstrate more than efficiency improvements — they must show validation, governance structures, auditability, and regulatory compliance.
The session helps biometrics leaders transition from early-stage experimentation to dependable, submission-ready AI implementations while preparing for intensified regulatory and legal examination.
Core Discussion Topics
Three principal themes will structure the conversation:
From experimentation to accountability: Exploration of why 2026 represents a pivotal moment for AI adoption in biometrics, and the potential consequences when teams neglect establishing foundational workflows, validation protocols, and governance frameworks.
The regulatory and legal landscape: Analysis of how FDA signals, including initiatives around Agentic AI, are influencing expectations for AI review, compliance requirements, and coordination among biometrics, regulatory, and legal departments.
Practical AI applications in 2026: Identification of which biometrics timeline components can compress today, which use cases demonstrate genuine value versus theoretical potential, and guidance for determining where AI implementation serves organizations best.
Featured Speakers
Panelists:
- Hanrui Zhang — DHT Review Lead, U.S. FDA
- Yali Li — Vice President of Biostatistics & Data Management, bioMerieux
- Ran He — Founder, THC Lawyers
Moderator:
- Louise Liu, PhD — CEO, Hill Research
Event Details
- Date: January 5, 2026 (Monday)
- Time: 2:00 - 3:00 PM ET
- Format: Live public webinar via Zoom
Who Should Attend
The webinar targets biostatistics professionals, data scientists, and clinical development decision-makers from pharmaceutical, biotechnology, and biometrics organizations preparing for expanded AI integration and heightened accountability requirements in regulated clinical settings.